What is Xention?
Xention operates at the forefront of biotechnology, specializing in the discovery and development of ion channel-modulating drugs. The company leverages an innovative approach to design potent and selective small-molecule therapeutics, specifically targeting Kv1.5 and Kir3.1/3.4 channels. These targets are recognized as critical pathways for managing atrial fibrillation, a condition that remains a significant challenge in modern cardiology.
Beyond its internal research capabilities, Xention has established high-value partnerships, most notably with Servier, to expand the reach of its Kv1.5 program. This collaborative model allows the company to maintain a lean operational structure while maximizing the clinical potential of its pipeline across international markets. By focusing on highly specific ion channel modulation, Xention distinguishes itself from broader pharmaceutical competitors, positioning its assets as essential components of future cardiovascular care.
How much funding has Xention raised?
Xention has raised a total of $44.9M across 4 funding rounds:
Series A
$5.7M
Series C
$6.5M
Series B
$20M
Series D
$12.7M
Series A (2003): $5.7M with participation from MVM Life Science Partners, Albany Ventures, BTG, and SPARK Ventures
Series C (2003): $6.5M led by MVM Life Science Partners and BTG International
Series B (2005): $20M supported by MVM, Enterprise VCT plc, Isis Equity Partners, Albany Ventures, Quester, ABN AMRO Capital of Amsterdam, BTG International, and Cr�dit Agricole Private Equity
Series D (2010): $12.7M featuring Seroba-Kernel Life Sciences Ltd
Key Investors in Xention
Seroba-Kernel Life Sciences Ltd
A European life sciences venture capital firm focused on investing in biotech and medtech innovations to support entrepreneurs in realizing their scientific ambitions.
MVM Life Science Partners
A specialized investment firm dedicated to the life sciences sector, providing strategic capital to companies developing transformative healthcare technologies.
BTG International
A global healthcare company focused on developing and commercializing products for critical care and specialty medicine, often acting as a strategic partner in drug development.
What's next for Xention?
With the recent strategic investment, Xention is well-positioned to accelerate its clinical milestones and deepen its research into ion channel modulation. The company's forward-looking strategy centers on the continued validation of its lead candidates and the expansion of its collaborative network. As the firm moves deeper into the development lifecycle, the focus will likely shift toward optimizing regulatory pathways and preparing for potential commercialization phases.
The integration of advanced drug design methodologies will remain a cornerstone of Xention's operational strategy. By maintaining its focus on high-unmet-need indications, the company is poised to deliver significant value to both its stakeholders and the broader medical community. Future growth will likely be defined by the successful progression of its partnership-backed programs and the potential for further pipeline diversification in the therapeutic space.
